Physician profile
Robert Levine
NPI 1700837234
$19,650.09
in general payments reported to CMS, 2019-2025
38 companies · $4,020 in 2025
The $4,020 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,344 · 2020: $1,531 · 2021: $2,030 · 2022: $2,824 · 2023: $2,969 · 2024: $3,933 · 2025: $4,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,383.52 |
| Education | $537.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,784.94 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $2,591.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,455.23 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $1,576.09 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,270.39 | 2019-2025 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $1,131.91 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,119.70 | 2019-2025 | Taltz, Ebglyss |
| Biofrontera INC. | $1,011.38 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Genzyme Corporation | $671.95 | 2019-2025 | |
| Amgen INC. | $552.28 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $547.42 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $496.27 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $482.62 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $388.59 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $381.63 | 2022-2024 | Vtama |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.